当前位置: X-MOL 学术Lancet Global Health › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Access, Watch, and Reserve antibiotics in India: challenges for WHO stewardship
The Lancet Global Health ( IF 34.3 ) Pub Date : 2017-11-01 , DOI: 10.1016/s2214-109x(17)30365-0
Patricia McGettigan , Peter Roderick , Abhay Kadam , Allyson M Pollock

In its most recent Model List of Essential Medicines,1 WHO adopted a new classification for antibiotics. This new model comprises three categories: Key Access antibiotics (eg, β-lactam, aminoglycoside, and first-generation or second-generation cephalosporin antibiotics) that “should be widely available, affordable and quality-assured”;1 Watch Group antibiotics (including most of the highest priority critically important antimicrobials for human medicine—eg, macrolides, quinolones, glycopeptides, penems, and third-generation cephalosporins)2 recommended only for specific, limited indications; and Reserve Group antibiotics (eg, fourth-generation and fifth-generation cephalosporins, aztreonam, polymixins) for situations when all alternative antibiotics have failed.

中文翻译:

印度获取,观察和储备抗生素:世卫组织管理工作面临的挑战

在其最新的基本药物标准清单中,1世卫组织采用了新的抗生素分类。这个新模型包括三类:“应该广泛获得,负担得起并且有质量保证的”关键获取抗生素(例如,β-内酰胺,氨基糖苷和第一代或第二代头孢菌素抗生素);1观察组抗生素(包括对人类医学最重要的最重要的至关重要的抗微生物药物,例如大环内酯类,喹诺酮类,糖肽类,青霉素类和第三代头孢菌素)2仅建议用于特定的,有限的适应症;当所有替代抗生素均无效时,使用和储备组抗生素(例如,第四代和第五代头孢菌素,氨曲南,多纤菌素)。
更新日期:2017-10-10
down
wechat
bug